Novartis AG improved its full-year profit outlook on Tuesday after stronger demand for newer medicines helped offset generic ...
Novartis lifted the veil on its phase 3 wins in relapsing multiple sclerosis (RMS) announced in early September. | In new ...
The Swiss drugmaker cited solid sales growth and productivity gains, even as recent clinical-trial setbacks hit its bottom line in the third quarter.
Investor Relations Executive Director - Isabella Singh ...
By Patricia Weiss, Bhanvi Satija and Marleen Kaesebier ZURICH/LONDON, Oct 27 (Reuters) - Novartis booked a $1.9 billion ...
Two late-stage clinical failures of high-value projects have not changed CEO Vas Narasimhan’s projection for Novartis over ...
Novartis (NYSE:NVS) reported third-quarter sales growth and margin expansion, supported by demand for priority medicines and ...
Novartis CEO, Vas Narasimhan, discusses how AI is beginning to impact the company’s operations. Narasimhan was speaking to ...
Novartis raised 2026 core operating income guidance to flat or low-single-digit growth while Q3 net income fell 70% to $1.196 ...
SALES FORECAST: The Swiss drugmaker is expected to report quarterly sales of $14.9 billion, according to consensus estimates provided by Visible Alpha. For the same quarter last year, the company ...
A multiple sclerosis treatment from Novartis cut by a third the rates of relapses that people with the condition have ...
ZURICH/LONDON, Oct 27 (Reuters) - Novartis raised its full-year core operating income guidance on Tuesday but also booked a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results